MGP Ingredients to Attend Lambert, Edwards & Associates 11th Annual SMID-West Investor Conference
Apr 14, 2016 20:15 pm UTC| Business
ATCHISON, Kan., April 14, 2016 -- MGP Ingredients, Inc. (Nasdaq:MGPI), a leading supplier of premium distilled spirits and specialty wheat proteins and starches, today announced that Gus Griffin, President and CEO, and...
CareDx Announces $22 Million Private Placement
Apr 14, 2016 20:14 pm UTC| Business
BRISBANE, Calif., April 14, 2016 -- CareDx, Inc. (NASDAQ:CDNA) (“CareDx” or the “Company”), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,...
Glen Burnie Bancorp Declares 1Q 2016 Dividend
Apr 14, 2016 20:14 pm UTC| Business
GLEN BURNIE, Md., April 14, 2016 -- Glen Burnie Bancorp (NASDAQ:GLBZ), parent company of The Bank of Glen Burnie®, announced that its Board of Directors declared a regular dividend of ten cents ($0.10) per share of...
StoneMor Partners L.P. Announces Public Offering of Common Units
Apr 14, 2016 20:11 pm UTC| Business
TREVOSE, Pa., April 14, 2016 -- StoneMor Partners L.P. (NYSE:STON) (“StoneMor”) announced today a public offering, subject to market and other conditions, of 2,000,000 common units representing limited partner interests...
Talyst to Exhibit at 50th Annual ACHCA Convocation & Exhibition
Apr 14, 2016 20:07 pm UTC| Business
KIRKLAND, Wash., April 14, 2016 -- The Talyst Long-Term Care Division, a leader in automated medication management for skilled nursing facilities, will be participating in the 50th Annual American College of Health Care...
Nanometrics Introduces the Atlas® III for Critical Dimension and Thin Film Process Control
Apr 14, 2016 20:05 pm UTC| Business
MILPITAS, Calif., April 14, 2016 -- Nanometrics Incorporated (NASDAQ:NANO), a leading provider of advanced process control systems, today announced the launch of Atlas® III, its latest flagship system for optical...
Apr 14, 2016 20:05 pm UTC| Business
NEW HAVEN, Conn., April 14, 2016 -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2...